Sarepta’s Stocks Drop 50% Following Middling Trial Data for Gene Therapy
On January 7th, Sarepta Therapeutics reported the first part results of its Phase 2 clinical trial that evaluated the gene transfer therapy, SRP-9001. Although the delivery of the therapy increased …
Read More